Clinical Trial Update: A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients [Phase 2]

View source ↗

Summary

A completed Phase II trial evaluating the efficacy and safety of dovitinib (TKI258) in advanced scirrhous gastric carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Dovitinib (dovitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Adenocarcinoma, Scirrhous, Linitis Plastica | Phase 2 | Status: COMPLETED